209256-41-7

Basic information

• Product Name: 2,3-Dihydro-1-benzofuran-4-ylmethanol
• Synonyms: 2,3-Dihydro-1-benzofuran-4-ylmethanol;4-BenzofuranMethanol, 2,3-dihydro-;2,3-Dihydro-4-benzofuranMethanol
• CAS NO: 209256-41-7
• Molecular Formula: C₉H₁₀O₂
• Molecular Weight: 150.17
• Mol File: 209256-41-7.mol

Chemical Properties

• Boiling Point: 282.1°C at 760 mmHg
• Flash Point: 132.8°C
• Appearance: /
• Density: 1.217g/cm³
• Vapor Pressure: 0.00162mmHg at 25°C
• Refractive Index: 1.594
• PKA: 14.18±0.10(Predicted)
• CAS DataBase Reference: 2,3-Dihydro-1-benzofuran-4-ylmethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dihydro-1-benzofuran-4-ylmethanol(209256-41-7)
• EPA Substance Registry System: 2,3-Dihydro-1-benzofuran-4-ylmethanol(209256-41-7)

Safety Data

• Hazardous Substances Data: 209256-41-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,3-Dihydro-1-benzofuran-4-ylmethanol is used as a key intermediate compound for the synthesis of 4-substituted anilides. These anilides are selective melatonin MT2 receptor agonists, which have potential applications in the treatment of various conditions such as sleep disorders, circadian rhythm regulation, and cognitive impairments.
In the preparation of these 4-substituted anilides, 2,3-Dihydro-1-benzofuran-4-ylmethanol serves as a crucial building block, allowing for the development of novel and effective therapeutic agents targeting the melatonin MT2 receptor.

InChI:InChI=1/C9H10O2/c10-6-7-2-1-3-9-8(7)4-5-11-9/h1-3,10H,4-6H2

Upstream product

• 209256-42-8 2,3-dihydro-1-benzofuran-4-carbaldehyde 
• 166599-84-4 benzofuran-4-carboxylic acid 
• 209256-40-6 2,3-dihydrobenzofuran-4-carboxylic acid 

Downstream Products

• 209256-42-8 2,3-dihydro-1-benzofuran-4-carbaldehyde 
• 209257-15-8 trans-[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methanamine 
• 851390-82-4 4-(2,3-dihydro-benzofuran-4-ylmethyl)-benzoic acid 
• 851390-98-2 4-(2,3-dihydro-benzofuran-4-ylmethyl)-phenylamine 
• 851390-71-1 4-(2,3-dihydro-benzofuran-4-ylmethyl)-benzaldehyde 

Relevant articles and documents

FACTOR XIIA INHIBITORS

This invention relates to compoundsof formula (I)and methods of treatment using the compounds. The invention also relates to processes and methods for producing the compounds of the invention. The compounds of the invention are modulators of Factor XII (e.g. Factor XIIa). In particular, the compounds are inhibitors of Factor XIIa and may be useful as anticoagulants.

ACYL GUANIDINE SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure wherein n is 1 to 5; X is N or C-R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.

BENZODIOXOLE, BENZOFURAN, DIHYDROBENZOFURAN, AND BENZODIOXANE MELATONERGIC AGENTS

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

Acyl guanidine sodium/proton exchange inhibitors and method

Acyl guanidines are provided which are sodium/proton exchange (NHE) inhibitors which have the structure STR1 wherein n is 1 to 5; X is N or C--R5 wherein R5 is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; and R1, R2, R3 and R4 are as defined herein, and where X is N, R1 is preferably aryl or heteroaryl, and are useful as antianginal and cardioprotective agents. In addition, a method is provided for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia employing the above acyl guanidines.